Skip to main content

TNF inhibitor

virus,COVID,Vaccine, booster

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

CDC/MMWR
Jan 27, 2022

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.



The ACIP

Read Article
ICYMI: Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/KsnQxYXHkI

Dr. John Cush @RheumNow( View Tweet )

Jan 22, 2022
ICYMI: Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/VMEMLod8EP https://t.co/O6l5eLfFxo
Dr. John Cush @RheumNow( View Tweet )
Jan 16, 2022
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.




  1. Study 126 rheumatic disease (RMD) patients showed that

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen

Read Article
heart.jpg (keep)

Best of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?https://t.co/RbOlrnW54O https://t.co/iDlqwv32zs
Dr. John Cush @RheumNow( View Tweet )
Dec 09, 2021
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Dec 08, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
TNF Inhibitor Panel Discussion: ACR21 Annual Meeting https://t.co/Kpj80YoDmN https://t.co/AChUVw17oc
Dr. John Cush @RheumNow( View Tweet )
Dec 06, 2021
FDA.Safety.jpg

FDA Puts Boxed Warnings on JAK Inhibitors

Dec 06, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
TNF inhibitors and radiographic progression in axSpA A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease.https://t.co/Gn9vFlq0Bd https://t.co/CXdlU0HQG8
Dr. John Cush @RheumNow( View Tweet )
Dec 06, 2021
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Watch: TNFi in axSpAhttps://t.co/uS01KNDgIH https://t.co/eb0W3fBKhq
Dr. John Cush @RheumNow( View Tweet )
Dec 02, 2021
Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.https://t.co/O90HInaS7z https://t.co/MdHVyxfkaW
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
Watch Now: Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448. ( @Janetbirdope, @drdavidliew, @ejdein1)https://t.co/UHmgmlrIqg https://t.co/0y03TFtJI6
Dr. John Cush @RheumNow( View Tweet )
Nov 29, 2021
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
Ultra Low Doses of Rituximab in RA: Dr. Eric Dein ( @ejdein1) and Nathan den Broeder \discuss abstract #1443 presented at the #ACR21 annual meeting.https://t.co/DpxkF5ffbt

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021
×